

# Index to Volume 11

The index to Volume 11 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in

*Clinical Pharmacy*, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages	Issue	Pages
January	1-92	July	571-656
February	93-204	August	657-742
March	205-280	September	743-822
April	281-374	October	823-904
May	375-454	November	905-988
June	455-570	December	989-1052

## Subject Index

### A

#### Absorption

anti-infective agents; intraperitoneal, CAPD, 246  
metoclopramide hydrochloride; peritoneal dialysis, 174

**Acetaminophen:** fever; therapy, pediatrics, review, 1005

#### Acquired immunodeficiency syndrome

didanosine; therapy, FDA approvals, 4  
566C80; *P. carinii* pneumonia, treatment IND, FDA approvals, 99  
foscarnet sodium; cytomegalic inclusion disease therapy, FDA approvals, 4

ganciclovir; cytomegalic inclusion disease therapy, liver toxicity, 432

zidovudine; therapy, DUE criteria, 63

#### Adenosine use; evaluation, criteria, 727

#### Administration

Food and Drug Administration; procedures, changes, new-drug approvals, 574

#### Adolescents

antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553

antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553

benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553

parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553

Adrenergic agents, see Sympathomimetic agents

Adverse drug reactions report form, 85, 649

#### Advertising Index

92, 204, 280, 374, 454, 570, 656, 742, 822, 904, 988, 1042

#### Aerosols;

$\beta$  agonists; regular vs. as-needed, asthma therapy, 877

Age; patients; home parenteral nutrition therapy, toxicity, 543

#### Agency for Health Care Policy and Research; protocols; pain therapy, 309, 391

#### AIDS, see Acquired immunodeficiency syndrome

Alcohols; cetyl; combination, colfosceril palmitate, tylospalox; adult respiratory distress syndrome therapy, neonate, 880; use evaluation criteria, 355

Aldesleukin; marketing; FDA approvals, 669

Allergies; fentanyl; diffuse rash, transdermal patches, 222

Aluminum; blood levels; sucrlafate toxicity, deferoxamine therapy, 636

Amantadine; hyperprolactinemia; therapy, psychotropic toxicity, 851

American Society of Hospital Pharmacists; protocols; antimicrobial prophylaxis, surgery, 483; globulin immune, i.v. therapy, 117

Amino acids

choline; cognition disorders therapy, FDA disapprovals, 467

marketing; cognition disorders therapy, FDA dis-

provials, 467  
**Aminoglycosides:** intraperitoneal; absorption, CAPD, 246

**Aminophylline** availability; liquid, enteral administration, 428 use; evaluation, criteria, 1033

**Amphotericin B** candidiasis; therapy, burns, infant, 883 use; evaluation, bladder irrigation, criteria, 809

**Anabolic agents;** steroids; hyperfibrinogenemia therapy, 968

**Analgesics and antipyretics** acetaminophen fever therapy, pediatrics, review, 1005 aspirin; fever therapy, pediatrics, review, 1005

fentanyl; adverse reactions, transdermal patches, 222; transdermal patches, 22 ibuprofen; fever therapy, pediatrics, review, 1005

morphine sulfate; Baxter Infusor, PCA, postoperative pain therapy, 342; intrathecal and i.v. PCA vs. PCA alone, postoperative pain, 958; toxicity, muscle spasticity, midazolam therapy, 57

pain; protocols, therapy, 309, 391

**Anemia;** dapsone; hemolytic, toxicity, therapy, 800

**Anesthetics;** toxicity; nausea and vomiting, abdominal surgery, 965

**Anesthetics, local** lidocaine, combination, procaine; pain therapy, s.c. injection sites, 347

pain; protocols, therapy, 391

**Angiotensin-converting enzyme inhibitors;** labeling; warnings, risks, pregnancy, 467

**Antiarrhythmic drugs,** see **Cardiac drugs**

**Anti-infective agents** dosage schedules; therapy, postantibiotic effect, 876

566C80; *P. carinii* pneumonia, treatment IND, FDA approvals, 99

surgery; prophylaxis, ASHP protocols, 483

toxicity; endocrine disorders, HIV infections, therapy, 705

postantibiotic effect, factors, 865

**Antibiotics** dosage schedules; therapy, postantibiotic effect, 876

mechanism of action; postantibiotic effect, 865

toxicity; endocrine disorders, HIV infections, therapy, 705

vancomycin; intraperitoneal, absorption, CAPD, 246

**Antibodies;** monoclonal; antiendotoxin, DUE criteria, 257

sepsis therapy, 223; sepsis therapy, criteria, 255

**Anticoagulants** heparin; vs. sodium chloride, i.v. lock flushing, 797

ticlopidine hydrochloride; FDA approvals, 99

toxicity; hemorrhage, dental surgery, 857

warfarin sodium; interactions, tetracycline, potentiation, prothrombin time, 806; toxicity, intramural hematoma of the small intestine, 632

**Anticonvulsants** eclampsia; and preeclampsia therapy, 236

ethosuximide and phenobarbital; clearance, peritone-

**Antivirals**  
 didanosine; AIDS therapy, FDA approvals, 4; DUE criteria, 885  
 foscarnet sodium; cytomegalic inclusion disease therapy, AIDS, FDA approvals, 4  
 ganciclovir; liver toxicity, cytomegalic inclusion disease therapy, AIDS, 432  
 toxicity; endocrine disorders, HIV infections, therapy, 705  
 zalcitabine; AIDS buyers groups, FDA actions, 385; marketing, FDA approvals, accelerated drug review policy, 747  
 zidovudine; DUE criteria, 63  
 zidovudine and zalcitabine; combined therapy, HIV infections, 747

**Anxiolytics, sedatives and hypnotics**; triazolam; labeling changes, package inserts, FDA approvals, 467; product withdrawal, United Kingdom, 9

**Arrhythmia**; therapy; toxicity, review, 714

**Arthritis**  
 nabumetone; rheumatoid, therapy, FDA approvals, 381

oxaprozin; rheumatoid, therapy, 591

**ASHP Commission on Therapeutics**; protocols; antimicrobial prophylaxis, surgery, 483; i.v. globulin immune, 117

**Asians**; Koreans; phenylpropanolamine, toxicity, hypertension, lack, 168

**Aspirin**  
 eclampsia; and preeclampsia therapy, 236  
 fever; therapy, pediatrics, review, 1005

**Astemizole**; toxicity; cardiovascular, labeling, warnings, 825

**Asthma**  
 β agonists; therapy, aerosols, dosage schedules, 877  
 sympathomimetic agents; β agonists, therapy, controversies, 13

**Atacurium besylate**; use; evaluation, criteria, 435

**Availability, drugs**, see Drugs, availability

**Azithromycin**  
 marketing; delay, Pfizer, 218; FDA approvals, 98  
 pharmacology, 137

## B

**Bacterial infections**  
 antibodies; antiendotoxin monoclonal, therapy, 223;  
 antiendotoxin monoclonal, therapy, criteria, 255;  
 antiendotoxin monoclonal, therapy, DUE criteria, 257

anti-infective agents; prophylaxis, surgery, ASHP protocols, 483

cefpodoxime proxetil; bacterial, therapy, FDA approvals, 999

cefprozil; therapy, FDA approvals, 295  
 lomefloxacin hydrochloride; therapy, FDA approvals, 458

temafloxacin hydrochloride; therapy, FDA approvals, 381

**Barbiturates**; pain; protocols, therapy, 391

**Basal ganglia diseases**; psychotherapeutic agents; toxicity, therapy, DUE criteria, 553

**Benzodiazepine antagonists**; flumazenil; FDA approvals, 287

**Benzodiazepines**  
 drug use; evaluation, criteria, therapy, extrapyramidal side effects, 553

overdose; toxicity, flumazenil therapy, 287  
 pain; protocols, therapy, 391

**Beractant**; use; evaluation, criteria, 357

**Bioavailability**, see Drugs, availability

**Biologics**; approvals; FDA, 1991, 208

**Blood levels**  
 aluminum; succinate toxicity, deferoxamine therapy, 636

ceftriaxone; i.m., concentrated, pediatrics, 961  
 cholesterol; and HDL monitoring, coronary disease, 378

ciprofloxacin; and milk levels, 352  
 ethosuximide and phenobarbital; decreased, peritoneal dialysis, 1030

fentanyl; transdermal patches, pain therapy, 22  
 ondansetron hydrochloride; pharmacokinetics, therapy, cisplatin toxicity, 1026

phenobarbital and ethosuximide; decreased, peritoneal dialysis, 1030

theophylline; aminophylline availability, enteral administration, 428

**Book Reviews**, 92, 277, 373, 565, 655, 742, 897,

*Advances in Pain Research and Therapy, Volume 18: The Design of Analgesic Clinical Trials*, 92

*Applied Therapeutics: The Clinical Use of Drugs*, Fifth

*Edition*, 897

*The Biochemical Basis of Neuropharmacology, Sixth Edition*, 655

**Clinical Immunotoxicology**, 900

**Combined Modality Cancer Therapy: Radiation and Infusional Chemotherapy**, 565

**Data Collection Forms in Clinical Trials**, 373

**Drugs in Gastroenterology**, 565

**Guide to Clinical Trials**, 277

**Handbook of Basic Pharmacokinetics . . . including Clinical Applications**, Fourth Edition, 901

**Manual of Antibiotics and Infectious Diseases**, Seventh Edition, 742

**Neoplastic Diseases: Fundamentals of Clinical Oncology**, 901

**Pharmacokinetics and Pharmacodynamics, Volume 3: Peptides, Peptides, and Proteins**, 277

**Books Received**, 198, 374, 454, 570, 655, 742, 904, 1042

**Bromocriptine**; hyperprolactinemia; therapy, psychotropic toxicity, 851

**Burns**  
 amphotericin B; candidiasis therapy, infant, 883  
 fluconazole; candidiasis therapy, lack, infant, 883

## C

### Calcium antagonists

hyperfibrinogenemia; therapy, 968

new drugs; advantages, 549

nimodipine; cerebrovascular ischemia therapy, 350

verapamil hydrochloride; pharmacokinetics, intact capsules vs. sprinkled on food, 539

**Calcium regulators**; pamidronate disodium; hypercalcemia therapy, FDA approvals, 220

**Cancer**, see Antineoplastic agents

**Cancer drugs**, see Antineoplastic agents

**Candidiasis**  
 amphotericin B; therapy, burns, infant, 883  
 fluconazole; therapy, lack, burns, infant, 883

**Capsules**; verapamil hydrochloride; intact vs. sprinkled on food, equivalence, pharmacokinetics, 539

**Carbamazepine**; concomitant therapy, 632

**Carcinoma**; adesleukin; renal cell, therapy, FDA approvals, 669

**Cardiac drugs**  
 adenosine; DUE criteria, 727

antiarrhythmic agents; therapy, toxicity, review, 714

dobutamine; congestive heart failure, long-term therapy, 618

flecainide; interactions, implanted cardiac devices, 48

moricizine; interactions, implanted cardiac devices, 48

**Cefazolin sodium**; toxicity; seizures, intraventricular injections, 104

**Cefpodoxime proxetil**; marketing; FDA approvals, 999

**Cefprozil**; marketing; FDA approvals, 295

**Ceftriaxone**; reconstitution; i.m., pharmacokinetics and toxicity, pediatrics, 961

**Cellulose**; hemorrhage; prophylaxis, dental surgery, anticoagulant toxicity, 857

**Central nervous system drugs**; cognition activators; FDA disapprovals, 467

**Cephalosporins**  
 cefazolin sodium; toxicity, seizures, intraventricular injections, 104

cefpodoxime proxetil; FDA approvals, 999

cefprozil; FDA approvals, 295

cefratixone; concentrated, pharmacokinetics, toxicity, pediatrics, 961

intraperitoneal; absorption, CAPD, 246

**Cerebral ischemia**; nimodipine; therapy, 350

**Cerebrovascular disorders**  
 nimodipine; ischemic stroke therapy, 350

ticlopidine hydrochloride; prophylaxis, FDA approvals, 99; therapy, review, 603

**Charcoal activated**; and methylene blue; therapy, dapsone toxicity, 800

**Cholelitholytic agents**; ursodiol; pruritus therapy, biliary cirrhosis, 672

**Cholesterol**; tests, laboratory, and HDL monitoring, coronary disease, 378

**Choline**; marketing; cognition disorders therapy, FDA disapprovals, 467

**Ciprofloxacin hydrochloride**; body distribution; blood and milk levels, 352

**Cisplatin**; toxicity; ondansetron therapy, pharmacokinetics, 1026

**Clarithromycin**  
 marketing; FDA approvals, 98

pharmacology, 137

**Clearance**, see Excretion

### Clinical Pharmacy

acknowledgment to reviewers—October 1, 1991, to September 30, 1992, 1032

instructions for submitting computer disks with revised manuscripts, 62

procedure for submission of manuscripts to journals published by the American Society of Hospital Pharmacists, 60

### Clinical studies

dobutamine; congestive heart failure, long-term therapy, 618

pravastatin sodium; hypercholesterolemia therapy, review, 677

**Cognition disorders**; therapy; amino acids, vitamins, marketing, FDA disapprovals, 467

**Cofosceril palmitate**; combination, alcohols, cetyl, tyloxapol; adult respiratory distress syndrome therapy, neomect, 880; use evaluation criteria, 355

**Collagen**; hemorrhage; microcrystalline prophylaxis, dental surgery, anticoagulant toxicity, 857

**Combined therapy**  
 acetaminophen and aspirin; fever, pediatrics, review, 1005

aspirin and acetaminophen; fever, pediatrics, review, 1005

zalcitabine and zidovudine; HIV infections, FDA approvals, 747

zidovudine and zalcitabine; HIV infections, FDA approvals, 747

**Commentaries**, 350, 549, 714, 797, 876, 968

### Complexes

*Haemophilus b oligosaccharide conjugate vaccines*; equivalency, immunogenicity, pediatrics, 332

*Haemophilus b polysaccharide conjugate vaccines*; equivalency, immunogenicity, pediatrics, 332

**Compliance**; patients; calcium antagonists therapy, 549

### Concentration

antibiotics; postantibiotic effect, 865

ceftriaxone; i.m., pharmacokinetics, toxicity, pediatrics, 961

globulin immune; injections, administration rate, toxicity, 1022; reconstitution, dextrose vs. water for injection, 628

**Control quality**; zalcitabine; problems, AIDS buyers groups, 385

**Coronary disease**; tests, laboratory; cholesterol and HDL monitoring, 378

**Correction Notices**, 14, 308, 585, 750, 829  
 Advances in the treatment of unstable angina pectoris (Nov 1991, Therapy Review), 14

American Academy of Pediatrics issues recommendations on treatment of Lyme disease (Oct 1991, News), 14

Clarithromycin and azithromycin: New macrolide antibiotics (Feb 1992, Drug Review), 308

Parenteral nutrition in pediatric patients (May 1988, Therapy Review), 750

Treatment with digoxin immune Fab (Nov 1991, Letters), 14

Review of 1991 shows 30 new drugs, several important biologics cleared for marketing (Mar 1992, News), 585

Table of contents (Aug 1992), 829

### Cost

*Haemophilus b oligosaccharide conjugate vaccines*; immunization, pediatrics, 332

*Haemophilus b polysaccharide conjugate vaccines*; immunization, pediatrics, 332

zalcitabine; therapy, 747

**CP Continuing Education**, 77, 189, 261, 442, 559, 640, 731, 811, 892, 976, 1039

**Creams**; lidocaine, combination, prilocaine; anesthesia, pain, s.c. injection sites, 347

**Current Literature**, 87, 197, 273, 368, 448, 562, 652, 735, 819, 895, 978, 1040

**Cytomegalic inclusion disease**  
 foscarnet sodium; therapy, AIDS, FDA approvals, 4

ganciclovir; therapy, liver toxicity, AIDS, 432

**Cytotoxic agents**, see Antineoplastic agents

## D

**Dapsone**; toxicity; hemolytic anemia, methemoglobinemia, therapy, 800

**ddI**, see Didanosine

**Deferoxamine mesylate**; therapy; aluminum overload, suicidal toxicity, CAPD, 636

### Depression

serotonin reuptake inhibitors; therapy, review, 930

sertraline hydrochloride; therapy, FDA approvals, 381

therapy; geriatrics, 96

**Devices**

Baxter Infusor; morphine PCA, postoperative pain therapy, 342  
implants; cardiac, interactions, antiarrhythmic agents, 48  
metrology; cups, spoons, droppers, drug overdose, 220

**Dextrose:** comparison, water for injection; globulin immune reconstitution, toxicity, 628

**Diabetes mellitus**

electrolytes, combination, polyethylene glycol; gastric lavage, protocols, 751  
metoclopramide hydrochloride; pharmacokinetics, C<sub>A</sub>PD, 174

**Dialysis:** peritoneal; clearance, ethosuximide and phenobarbital, 1030; continuous ambulatory, anti-infective agents absorption, 246; metoclopramide pharmacokinetics, 174; sucralfate, toxicity, aluminum overload, 636

**Diazepam:** eclampsia; and preeclampsia therapy, 236

**Dianosine**

marketing; FDA approvals, 4  
use; evaluation, criteria, 885

**Diluents:** lidocaine; ceftiraxone, i.m., reconstitution, pediatrics, 961

**Diphenhydramine hydrochloride:** allergies; therapy, fentanyl adverse reactions, 222

**Diphtheria and tetanus toxoids and pertussis vaccines:** marketing; FDA approvals, 290

**Diuretics:** hydrochlorothiazide; hypertension therapy, phenylpropanamine effects, lack, 168

**Dobutamine:** heart failure; congestive, long-term therapy, 618

**Dosage**

adenosine; DUE criteria, 727

alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; DUE criteria, 355

aldesleukin, 669

aminophylline; DUE criteria, 1033

amphotericin B; DUE criteria, 809

analgesics and antipyretics; fever therapy, pediatrics, review, 1005

antibodies; monoclonal antidiotoxin, DUE criteria, 257

antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553

anti-infective agents; intraperitoneal, absorption, C<sub>A</sub>PD, 246

antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553

azithromycin, 98, 137

benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553

beractant; DUE criteria, 357

cetpodoxime proxetil, 999

cefprozil, 295

cisplatin; high, toxicity, ondansetron therapy, 1026

clarithromycin, 98, 137

danosine, 4; DUE criteria, 885

diphtheria and tetanus toxoids and pertussis vaccines; immunization, pediatrics, 290

dobutamine; congestive heart failure, long-term therapy, 618

doxazosin mesylate, 415

ethoxszimide and phenobarbital; clearance, peritoneal dialysis, 1030

felodipine, 9

fentanyl; adverse reactions, transdermal patches, 222

finasteride, 825

flumazenil, 287

foscarnet sodium, 4

*Haemophilus* b oligosaccharide conjugate vaccines; immunization, pediatrics, 332

*Haemophilus* b polysaccharide conjugate vaccines; immunization, pediatrics, 332

idarubicin, 152

$\gamma$ -interferon; review, 834

interferon gamma-1b; review, 834

lactase; lactose intolerance, reduced symptoms, 533

lomefloxacin hydrochloride, 458; review, 753

morphine sulfate; Baxter Infusor, PCA, postoperative pain therapy, 342

nabumetone, 381

omeprazole; ulcers, peptic esophagitis, DUE criteria, 177

overdose; benzodiazepines, flumazenil therapy, 287

dapsone, toxicity, hemolytic anemia, methemoglobinemia, 800; measuring cups, spoons, droppers, toxicity, 220

oxaproxin, 591

paclitaxel disodium, 220

parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553

phenobarbital and ethosuximide; clearance, peritoneal

dialysis, 1030  
pravastatin sodium, 99; hypercholesterolemia therapy, review, 677

quinapril hydrochloride, 220  
serotonin reuptake inhibitors; depression therapy, review, 930

sertaline hydrochloride, 381  
simvastatin, 290  
skeletal muscle relaxants; DUE criteria, 435

sumatriptan; DUE criteria, 972  
sumatriptan succinate; therapy, review, 919

temafloxacin hydrochloride, 381; review, 753  
theophylline; DUE criteria, 1033

ticlopidine hydrochloride, 99; review, 603  
ursodiol; pruritus therapy, biliary cirrhosis, 672

zalcitabine, 747

zidovudine; DUE criteria, 63

**Dosage forms**

drug administration systems; measuring cups, spoons, droppers, overdose, 220

fentanyl; transdermal patches, adverse reactions, 222;

transdermal patches, pain therapy, 22

**Dosage schedules**

$\beta$  agonists; aerosols, regular vs. as-needed, asthma therapy, 877

antibiotics; postantibiotic effect, 865; therapy, postantibiotic effect, 876

anti-infective agents; prophylaxis, surgery, ASHP protocols, 483; therapy, postantibiotic effect, 876

calcium antagonists; therapy, 549

dobutamine; congestive heart failure, long-term therapy, 618

nutrition; parenteral, chronic home therapy, toxicity, 543

oxaprozin, 591

triazolam; labeling changes, FDA approvals, 467

**Doxacurium chloride:** use; evaluation, criteria, 435

**Doxazosin mesylate:** pharmacology; review, 415

**Drug administration**

alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; intratracheal, adult respiratory distress syndrome, neonate, 880

$\gamma$ -interferon; chronic granulomatous disease therapy, 834

interferon gamma-1b; chronic granulomatous disease therapy, 834

serotonin reuptake inhibitors; depression therapy, review, 930

verapamil hydrochloride; equivalency, intact capsules vs. sprinkled on food, 539

**Drug administration rate:** globulin immune; i.v. infusion, concentrated, toxicity, 1022

**Drug administration routes**

$\beta$  agonists; regular vs. as-needed, asthma, 877

aminophylline; enteral administration, availability, 428

anti-infective agents; prophylaxis, surgery, ASHP protocols, 483

cefazolin sodium; intraventricular, toxicity, seizures, 104

deferoxamine mesylate; intraperitoneal, i.v., aluminum overload therapy, 636

fentanyl; transdermal patches, pain therapy, 22

intraperitoneal; anti-infective agents, absorption, C<sub>A</sub>PD, 246

mesalamine; rectal, inflammatory bowel disease therapy, 514

methotrexate; intramuscular, ectopic pregnancy therapy, 529

metoclopramide hydrochloride; i.p. vs. i.v. oral, pharmacokinetics, C<sub>A</sub>PD, 174

morphine sulfate; intrathecal and i.v. PCA vs. PCA alone, postoperative pain therapy, 958

olsalazine sodium; oral, inflammatory bowel disease therapy, 514

roentgenographic agents; ionic, epidural, toxicity, inadvertent intrathecal injection, 105

scopolamine; transdermal patches, hyperemesis gravidarum therapy, 830

**Drug administration sites**

fentanyl; transdermal patches, adverse reactions, 222

lidocaine, combination, prilocaine; anesthesia, pain, s.c. injections, 347

**Drug administration systems**

Baxter Infusor; morphine PCA, postoperative pain therapy, 342

devices; measuring cups, spoons, droppers, overdose, 220

**Drug interactions**

antiarrhythmic agents and devices; cardiac implants, impaired functioning, 48

azithromycin, 137

clarithromycin, 98; review, 753

cisplatin and ondansetron hydrochloride; pharmacokinetics, 1026

clarithromycin, 137

devices and antiarrhythmic agents; cardiac implants, impaired functioning, 48

food and verapamil hydrochloride; equivalency, intact capsules vs. sprinkled, 539

lomefloxacin hydrochloride; review, 753

ondansetron hydrochloride and cisplatin; pharmacokinetics, 1026

serotonin reuptake inhibitors; depression therapy, review, 930

surfactant and tests, laboratory; occult blood, interference, 625

temafloxacin hydrochloride; review, 753

tests, laboratory and surafatate; occult blood, interference, 625

tetracycline hydrochloride and warfarin sodium; potentiation, prothrombin time, 806

verapamil hydrochloride and food; equivalency, intact capsules vs. sprinkled, 539

warfarin sodium and tetracycline hydrochloride; potentiation, prothrombin time, 806

**Drug Reaction Alerts,** 87, 197, 273, 368, 448, 562, 852, 735, 819, 895, 978, 1040

**Drugs**

new; marketing, FDA approvals, 1991, 208

reconstitution; ceftiraxone, i.m., pharmacokinetics, toxicity, pediatrics, 961; globulin immune, dextrose vs. water for injection, 628

selection; antimicrobial prophylaxis, surgery, ASHP protocols, 483

**Drugs, adverse reactions, see Toxicity**

**Drugs, availability:** aminophylline; liquid, enteral administration, 428

**Drugs, body distribution**

ciprofloxacin hydrochloride; blood and milk levels, 352

metoclopramide hydrochloride; peritoneal dialysis, 174

**Drugs, investigational**

investigational new drugs; 566C80, *P. carinii* pneumonia, protocols, 99; taxol, ovarian neoplasms therapy, protocols, 912; zalcitabine, FDA actions, pre-marketing access, 385

new-drug applications; approvals, changes, FDA processing, 574

**Drug use**

evaluation; adenosine, criteria, 727; aminophylline, theophylline criteria, 1033; amphotericin B, bladder irrigation, criteria, 809; antidiotoxin monoclonal antibodies, criteria, 257; beractant, criteria, 357; didanosine, criteria, 885; Exosurf Neonatal, criteria, 355; omeprazole, criteria, 177; skeletal muscle relaxants, criteria, 435; sumatriptan criteria, 972; therapy, extrapyramidal side effects, 553; zidovudine, criteria, 63

fentanyl; diffuse rash, transdermal patches, 222

**Drug Criteria,** 63, 177, 257, 355, 435, 553, 727, 809, 885, 972, 1033

adenosine, 727

agents for extrapyramidal adverse effects, 553

amphotericin B bladder irrigation, 809

antidiotoxin monoclonal antibodies (HA-1A and E5), 257

beractant (Survanta), 357

colfosceril (Exosurf Neonatal), 355

didanosine, 885

omeprazole, 177

pancuronium bromide, vecuronium bromide, atracurium besylate, tubocurarine chloride, metocurine iodide, pipecuronium bromide, and doxacurium chloride, 435

sumatriptan, 972

theophylline (aminophylline), 1033

zidovudine, 63

**E****Eclampisia; therapy, 236**

**Editorial:** Who should receive antidiotoxin monoclonal antibody therapy? 255

**Electrolytes:** combination, polyethylene glycol; gastric lavage, diabetes mellitus, protocols, 751

**Endocrine diseases:** therapy; HIV infections related, 705

**Enzymes:** lactase; lactose intolerance, reduced symptoms, 533

**Epidemiology:** leukemia; adult acute, therapy, review, 767

**Epilepsy**

ethosuximide and phenobarbital; absence, clearance, peritoneal dialysis, 1030

phenobarbital and ethosuximide; absence, clearance,

## Annual Index

peritoneal dialysis, 1030  
**Equivalency**  
*Haemophilus b* oligosaccharide conjugate vaccines; immunogenicity, pediatrics, 332  
*Haemophilus b* polysaccharide conjugate vaccines; immunogenicity, pediatrics, 332  
verapamil hydrochloride; pharmacokinetics, intact capsules vs. sprinkled on food, 539  
**Equivalency, generic**; globulin immune; formulary selection, ASHP protocols, 117  
**Errors, medication; dosage**; measuring devices, 220  
**Erythromycin**; gastroparesis; therapy, effects, motilin, 917  
**Esophageal and gastric varices**;  $\beta$  blockers; gastrointestinal hemorrhage prophylaxis, 337  
**Esophagitis**; omeprazole; peptic, therapy, DUE criteria, 177  
**Ethoxsuximide**; phenobarbital; clearance, peritoneal dialysis, 1030  
**Excitation**  
ethoxsuximide and phenobarbital; clearance, peritoneal dialysis, 1030  
metoclopramide hydrochloride; clearance, CAPD, 174  
phenobarbital and ethoxsuximide; clearance, peritoneal dialysis, 1030

**F**

**Felodipine**; marketing; FDA approvals, 9  
**Fentanyl**  
adverse reactions; diffuse rash, transdermal patches, 222  
patches transdermal; pain therapy, 22  
**Fever**; analgesics and antipyretics; therapy, pediatrics, review, 1005  
**Finasteride**; marketing; FDA approvals, 825  
566C80; pneumonia; *P. carinii*, treatment IND, FDA approvals, 99  
**Flecainide**; interactions; implanted cardiac devices, 48  
**Fluconazole**; candidiasis; therapy, lack, burns, infant, 883  
**Flumazenil**; marketing; FDA approvals, 287  
**Fluvoxamine**; depression; therapy, review, 930  
**Food**; interactions; verapamil, open vs. intact capsules, pharmacokinetics, 539  
**Food and Drug Administration (U.S.)**  
approvals; aldesleukin marketing, 669; azithromycin, clarithromycin, marketing, 98; cefpodoxime marketing, 999; cefprozil marketing, 295; didanosine, foscarnet, marketing, 4; DTG vaccines marketing, 290; felodipine marketing, 9; finasteride marketing, 825; flumazenil marketing, 287; lomefloxacin marketing, 458; nabumetone marketing, 381; new-drug applications, changes, processing, 574; new drugs and biologicals, 1991, 208; pamidronate, marketing, 220; pravastatin, marketing, 99; quinapril, marketing, 220; sertraline marketing, 381; simvastatin marketing, 290; temafloxacin marketing, 381; ticlopidine, marketing, 99; triazolam labeling changes, package inserts, 467; zalcitabine, marketing, accelerated drug review policy, 747  
azithromycin; actions, toxicity reports, marketing delay, 218  
cognition activators; disapprovals, marketing, 467  
566C80; *P. carinii* pneumonia, treatment IND approvals, 99  
labeling; drug measuring devices, overdose, 220  
regulations; astemizole, terfenadine, warning labels, cardiovascular toxicity, 825; temafloxacin, toxicity, product withdrawal, 747  
taxol; treatment IND approvals, 912  
triazolam; actions, toxicity reports, 9  
zalcitabine; actions, AIDS buyers groups, quality problems, 385  
**Formularies**; globulin immune; product selection, ASHP protocols, 117  
**Foscarnet sodium**; marketing; FDA approvals, 4

**G**

**Ganciclovir**; toxicity; liver, cytomegalic inclusion disease therapy, AIDS, 432  
**Gastric lavage**; electrolytes, combination, polyethylene glycol; diabetes mellitus, protocols, 751  
**Gastrointestinal drugs**  
histamine H<sub>2</sub> antagonists; ulcer therapy, NSAID toxicity, review, 690  
mesalamine; inflammatory bowel disease therapy, 514  
misoprostol; ulcer therapy, NSAID toxicity, review, 690  
olsalazine sodium; inflammatory bowel disease therapy, 514  
omeprazole; DUE criteria, 177; ulcer therapy, NSAID toxicity, review, 690  
sucralfate; interference, occult blood tests, 625; toxicity, aluminum overload, deferoxamine therapy, CAPD, 636  
**Gastrointestinal hemorrhage**;  $\beta$  blockers; prophylaxis, cirrhosis, esophageal varices, 337  
**Gastroparesis**; erythromycin; therapy, 917  
**Gelatin**; sponges; hemorrhage prophylaxis, dental surgery, anticoagulant toxicity, 857  
**Geriatrics**  
depression; therapy, 96  
pain; therapy, protocols, 391  
**Globulin immune**  
reconstitution; dextrose vs. water for injection, toxicity, 628  
therapy; i.v., ASHP protocols, 117  
toxicity; side effects, concentrated injections, 1022  
**Granulomatous disease**  
 $\gamma$ -interferon; chronic, therapy, 834  
interferon gamma-1b; chronic, therapy, 834  
**Guidelines, treatment**, see **Protocols**

**H**

**HA-1A**  
see also **Nebacumab**  
sepsis; antiendotoxin monoclonal antibodies, therapy, 223  
**Haemophilus b** oligosaccharide conjugate vaccines; immunization; equivalency, immunogenicity, pediatrics, 332  
**Haemophilus influenzae**; immunization; conjugate vaccines, immunogenicity, pediatrics, 332  
**Headache**; sumatriptan; therapy, DUE criteria, 972  
**Health care**; home; parenteral nutrition, toxicity, 543  
**Heart failure**; dobutamine; congestive, long-term therapy, 618  
**Heavy metal antagonists**; deferoxamine mesylate; therapy, aluminum overload, sucralfate toxicity, CAPD, 636  
**Hematoma**; warfarin sodium; toxicity, intramural, small intestine, 632  
**Hemorrhage**; anticoagulants; toxicity, dental surgery, 857  
**Hemostatics**; therapy; anticoagulant toxicity, dental surgery, 857  
**Heparin**; flushes; toxicity, thrombocytopenia, thromboembolism, 797  
**HIV infections**  
didanosine; therapy, DUE criteria, 885  
therapy; associated endocrine disorders, 705  
zalcitabine; therapy, Roche premarketing access programs, 385  
zalcitabine and zidovudine; combined therapy, FDA approvals, 747  
zidovudine and zalcitabine; combined therapy, FDA approvals, 747  
**Hoffmann-La Roche Pharmaceuticals**; zalcitabine; investigational new drugs, premarketing access programs, 385  
**Hospitals**; length of stay; nausea and vomiting, anesthetic toxicity, surgery, 965  
**Hydrochlorothiazide**; hypertension; phenylpropanamine effects, lack, 168  
**Hyperalimentation**, see **Nutrition; parenteral**  
**Hypercalcemia**; pamidronate disodium; therapy, neoplasms, FDA approvals, 220  
**Hypercholesterolemia**  
pravastatin sodium; therapy, FDA approvals, 99; therapy, review, 677  
simvastatin; therapy, FDA approvals, 290  
**Hyperemesis gravidarum**; scopolamine; transdermal patches, 830  
**Hyperfibrinogenemia**; therapy, 968  
**Hyperprolactinemia**; psychotherapeutic agents; toxicity, therapy, 851  
**Hypertension**  
doxazosin mesylate; therapy, review, 415  
felodipine; therapy, FDA approvals, 9  
phenylpropanamine hydrochloride; toxicity, lack, 168  
quinapril hydrochloride; therapy, FDA approvals, 220  
**Hypotensive agents**  
doxazosin mesylate; review, 415  
ectampsia; and preeclampsia therapy, 236

**Ibuprofen**; fever; therapy, pediatrics, review, 1005  
**Idarubicin**; leukemia; nonlymphocytic, acute, therapy, 152  
**Immunization**  
diphtheria and tetanus toxoids and pertussis; vaccines, FDA approvals, 290  
*Haemophilus influenzae*; conjugate vaccines, immunogenicity, pediatrics, 332  
rabies; vaccines, human rabies immune globulin, 37  
**Immunogenicity**  
*Haemophilus b* oligosaccharide conjugate vaccines; equivalency, pediatrics, 332  
*Haemophilus b* polysaccharide conjugate vaccines; equivalency, pediatrics, 332  
**Immunosuppressive agents**; methotrexate; ectopic pregnancy therapy, 529  
**Immunotherapy**  
globulin immune; i.v. therapy, ASHP protocols, 117; reconstitution, dextrose vs. water for injection, 628; toxicity, concentrated injections, bone marrow transplantation, 1022  
 $\gamma$ -interferon; chronic granulomatous disease, 834  
 $\gamma$ -interferon gamma-1b; chronic granulomatous disease, 834  
nebacumab; sepsis, criteria, 255; sepsis, DUE criteria, 257  
sepsis; antiendotoxin monoclonal antibodies, 223  
Xomen-E5; sepsis, criteria, 255; sepsis, DUE criteria, 257  
**Implants**; heart; interactions, antiarrhythmic agents, 48  
**Inflammatory bowel disease**  
mesalamine; therapy, 514  
olsalazine sodium; therapy, 514  
**Injections**  
cefazolin sodium; intraventricular, toxicity, seizures, 104  
ceftazidime; i.m., concentrated, pharmacokinetics and toxicity, pediatrics, 961  
dobutamine; intravenous, congestive heart failure, long-term therapy, 618  
globulin immune; concentrated, i.v. infusion rate, toxicity, 1022; reconstitution, dextrose vs. water for injection, 628; i.v. therapy, ASHP protocols, 117  
heparin, comparison, sodium chloride; lock flushing, 797  
morphine sulfate; intrathecal and i.v. PCA vs. PCA alone, postoperative pain, 958  
pamidronate disodium; marketing, FDA approvals, 220  
patient-controlled analgesia; morphine, Baxter Infusion, postoperative pain therapy, 342  
roentgenographic agents; ionic, epidural, toxicity, inadvertent intrathecal administration, 105  
sodium chloride, comparison, heparin; lock flushing, 797  
subcutaneous; pain, lidocaine-prilocaine therapy, 347  
**Insomnia**; triazolam; therapy, labeling, changes, package inserts, FDA approvals, 467  
 $\gamma$ -**Interferon**; granulomatous disease; chronic, therapy, review, 834  
**Interferon gamma-1b**; granulomatous disease; chronic, therapy, review, 834  
**Irritating solutions**; amphotericin B; bladder, urinary anti-infectives, DUE criteria, 809

**K**

**Kidney failure**  
metoclopramide hydrochloride; pharmacokinetics, CAPD, 174  
sucralfate; toxicity, aluminum overload, deferoxamine therapy, CAPD, 636

**L**

**Labeling**  
angiotensin-converting enzyme inhibitors; warnings, risks, pregnancy, 467  
astemizole; warnings, cardiovascular toxicity, 825  
devices; dosage measuring, overdose, 220  
terfenadine; warnings, cardiovascular toxicity, 825  
triazolam; changes, FDA approvals, 467

**Lactase;** lactose intolerance; effects, reduced symptoms, 533

**Lactation;** ciprofloxacin hydrochloride; milk and blood levels, 352

**Lactose intolerance;** lactase; effects, reduced symptoms, 533

**Letters,** 13, 104, 222, 308, 386, 583, 674, 767

Asthma in children, 386

Beta-adrenergic agonists in asthma, 13

Danger of epidural use of ionic contrast media, 105

Diffuse rash associated with transdermal fentanyl, 222

Potential interaction between terfenadine and macrolide antibiotics, 675

Seizures after intraventricular cefazolin administration, 104

Topical capsaicin for osteoarthritis, 308

Use of cytomegalovirus immune globulin, 674

Use of sucrose, 387

Use of surfactant products, 583

Value of transdermal fentanyl, 584

**Leukemia;** therapy; acute, adult, review, 767

**Liocaine**

combination, prilocaine; anesthesia, pain, s.c. injection sites, 347

diluents; ceftriaxone, reconstitution, concentrated, pediatrics, 961

**Liver cirrhosis**

β blockers; gastrointestinal hemorrhage prophylaxis, 337

ursodiol; biliary, pruritus therapy, 672

**Liver diseases;** effects; astemizole, terfenadine toxicity, 825

**Lomefloxacin hydrochloride**

marketing; FDA approvals, 458

pharmacology; review, 753

**Lung diseases**

aminophylline; therapy, DUE criteria, 1033

theophylline; therapy, DUE criteria, 1033

## M

**Macrolides**

azithromycin; FDA approvals, 98; marketing delay, 218

Pfizer, 218; pharmacology, 137

clarithromycin; FDA approvals, 98; pharmacology, 137

erythromycin; gastroparesis therapy, effects, motilin, 917

**Magnesium sulfate;** eclampsia; and preeclampsia therapy, 236

**Marketing**

aldesleukin; FDA approvals, 669

azithromycin; delay, Pfizer, 218; FDA approvals, 98

cefodoxime proxetil; FDA approvals, 999

ceprozil; FDA approvals, 295

clarithromycin; FDA approvals, 98

cognition activators; FDA disapprovals, 467

diphtheria and tetanus toxoids and pertussis vaccines; FDA approvals, 290

felodipine; FDA approvals, 9

finasteride; FDA approvals, 825

flumazenil; FDA approvals, 381

lomefloxacin hydrochloride; FDA approvals, 458

nabumetone; FDA approvals, 381

new drugs; and biologicals, FDA approvals, 1991, 208

pamidronate disodium; FDA approvals, 220

pravastatin sodium; FDA approvals, 99

quinapril hydrochloride; FDA approvals, 220

sertraline hydrochloride; FDA approvals, 381

temafloxacin hydrochloride; FDA approvals, 381

ticlopidine hydrochloride; FDA approvals, 99

zalcitabine; FDA approvals, accelerated drug review policy, 747

**Mechanism of action**

antibiotics; postantibiotic effect, 865

azithromycin, 137

clarithromycin, 137

idarubicin, 152

lomefloxacin hydrochloride; review, 753

sertraline hydrochloride, 381

sumatriptan succinate; migraine therapy, review, 919

temafloxacin hydrochloride; review, 753

ticlopidine hydrochloride; cerebrovascular disorders therapy, review, 603

**Mesalamine;** inflammatory bowel disease; therapy, 514

**Methemoglobinemia;** dapsone; toxicity, therapy, 800

**Methotrexate;** pregnancy; ectopic, therapy, 529

**Methylene blue;** and charcoal activated; therapy, dapsone toxicity, 800

**Metoclopramide hydrochloride;** pharmacokinetics;

peritoneal dialysis, 174

**Meturine iodide;** use; evaluation, criteria, 435

**Metrology;** devices; dosage measuring, overdose potential, 220

**Midazolam hydrochloride;** muscle spasticity; therapy, morphine toxicity, 57

**Migraine**

sumatriptan; therapy, DUE criteria, 972

sumatriptan succinate; therapy, review, 919

**Misoprostol;** ulcers; therapy, NSAID toxicity, review, 690

**Monoamine oxidase inhibitors;** depression; therapy, geriatrics, 96

**Moricizine;** interactions; implanted cardiac devices, 48

**Morlum sulfate**

pain; postoperative, intrathecal and i.v. PCA vs. PCA, 958

patient-controlled analgesia; Baxter Infusor, postoperative pain therapy, 342

toxicity; muscle spasticity, midazolam therapy, 57

**Mortality**

β agonists; regular vs. as-needed, asthma therapy, 877

antiarrhythmic agents; toxicity, 714

**Mouthwashes;** tranexamatic acid; hemorrhage prophylaxis, anticoagulant toxicity, dental surgery, 857

**Muscle spasticity;** morphine sulfate; toxicity, midazolam therapy, 57

## N

**Nabumetone;** marketing; FDA approvals, 381

**Nadolol;** gastrointestinal hemorrhage; prophylaxis, cirrhosis, esophageal varices, 337

**Nausea**

anesthetics; and vomiting, toxicity, surgery, 965

ondansetron hydrochloride; and vomiting, therapy, cisplatin toxicity, 1026

**Nebacumab**

sepsis; antifendotoxin monoclonal antibodies, therapy, criteria, 255

**Neoplasms;** pamidronate disodium; hypercalcemia therapy, FDA approvals, 220

**News;** 4, 96, 208, 378, 458, 574, 669, 747, 825, 912, 991

acellular pertussis vaccine approved by FDA, 290

Adverse effects prompt withdrawal of temafloxacin, 747

Benzodiazepine antagonist approved by FDA, 287

Call for applications to conduct research on patient outcomes associated with pharmaceutical therapy in ambulatory-care setting, 467

CDC advises on management of persons exposed to multiple-drug-resistant tuberculosis, 991

Cefpodoxime marketing approved by FDA, 999

Cefprozil enters oral antibiotic market, 295

Cognitive enhancer illegal, says FDA, 467

Depression in elderly is common but undertreated, says expert panel, 96

Didanosine and foscamet marketed for use by patients with AIDS, 4

EPA seeks information on efficacy of sterilants and disinfectants, 295

Expert panel issues guidelines on asthma management, 295

False-positive viral antibody test results reported in influenza vaccine recipients, 220

FDA announces four initiatives for drug approval system, 574

FDA approves release of recombinant interleukin-2 product, 669

FDA approves treatment IND protocol for taxol, 912

FDA seeks changes in benzodiazepine packaging and labeling, 295

FDA seizes cold sterilizing solution, 220

FDA warns of overdose risk from dosage cups, 220

FDA warns quality of underground zalcitabine is poor; Roche expands premarketing access programs, 385

Federal task force revises recommendations for PCP prophylaxis, 670

Felodipine marketed as antihypertensive agent, 9

Finasteride approved for treatment of benign prostatic hyperplasia, 825

Free drug programs for indigent patients should be more accessible, says Senate committee on aging, 1000

Guidelines address systemic glucocorticosteroid use for infection management, 295

HDL testing should be routine part of assessments of coronary heart disease risk, says consensus panel, 378

Heavy use of inhaled β agonists associated with in-

creased risk of fatal or near-fatal asthma, study shows, 458

Lomefloxacin reaches U.S. market, 458

Nabumetone marketed for osteoarthritis, rheumatoid arthritis, 381

New labeling and patient insert for triazolam approved by FDA, 467

News Briefs, 9, 103, 221, 296, 385, 467, 576, 670, 750, 829, 912, 1000

Oral temafloxacin approved for U.S. market, 381

Pamidronate released for management of hypercalcemia of malignancy, 220

Pediatrics academy issues new guidelines for acellular pertussis vaccine use, 576

Pfizer delays marketing azithromycin, 218

Pravastatin reaches U.S. market, 99

Quinapril marketed as antihypertensive agent, 220

Results of ISIS-3 published, 576

Review of 1991 shows 30 new drugs, several important biologics cleared for marketing, 208

Sertaline cleared for marketing as antidepressant, 381

Tacrine made available under treatment IND protocol, 385

Talley to succeed Zellmer as editor of *AJHP and Clinical Pharmacy*, 750

Terfenadine and astemizole pose cardiovascular risks to certain patients, health professionals warned, 825

Third HMG-CoA reductase inhibitor marketed for cholesterol reduction, 290

Three studies examine angiotensin-converting-enzyme inhibitor prevention of heart failure, 999

Tickloidine approved for stroke prevention, 99

Treatment IND protocol announced for *Pneumocystis carinii* pneumonia, 99

Two macrolide antimicrobials approved for marketing, 98

United Kingdom suspends sales of triazolam; FDA to review safety data, 9

Upcoming Specialty Meetings, 9, 103, 221, 296, 385, 470, 576, 670, 750, 912, 1000

Warnings about use of angiotensin-converting-enzyme inhibitors in advanced pregnancy strengthened, 467

Working group issues report on aluminum contamination of parenteral nutrient solutions, 6

Zalcitabine approved under accelerated drug review policy, 747

**Nimodipine;** cerebrovascular disorders; ischemic stroke therapy, 350

**Nutrition**

diet; lactose intolerance, lactase effects, reduced symptoms, 533

parenteral; home therapy, side effects, 543

**Occult blood;** tests, laboratory; Gastrococcult vs. Hemoccult, interference, sulfarlate, 625

**Olsalazine sodium;** inflammatory bowel disease; therapy, 514

**Omeprazole**

ulcers; therapy, NSAID toxicity, review, 690

use; evaluation, criteria, 177

**Ondansetron hydrochloride;** pharmacokinetics; therapy, cisplatin toxicity, 1026

**Opiates;** pain; protocols, therapy, 391

**Osteoarthritis**

nabumetone; therapy, FDA approvals, 381

oxaprozin; therapy, 591

**Ovarian neoplasms;** taxol; treatment IND, FDA approvals, 912

**Oxaprozin;** arthritis; rheumatoid, and osteoarthritis, therapy, 591

**P**

**Package inserts;** patients; triazolam, changes, FDA approvals, 467

**Paclitaxel,** see Taxol

**Pain**

analgesics; protocols, therapy, 309

lidocaine, combination, prilocaine; anesthesia, s.c. injection sites, 347

morphine sulfate; postoperative, Baxter Infusor PCA, 342; postoperative, intrathecal and i.v. PCA vs. PCA alone, 958

therapy; protocols, 391

**Pamidronate disodium;** marketing; FDA approvals, 220

## Annual Index

**Pancuronium bromide;** use; evaluation, criteria, 435

**Parasympatholytic agents;** drug use; evaluation, criteria, therapy, extrapyramidal side effects, 553

**Parenterals,** see *Injections*

**Paroxetine;** depression; therapy, review, 930

**Patches transdermal**

- fentanyl; adverse reactions, diffuse rash, 222; pain therapy, 22
- scopolamine; hyperemesis gravidarum therapy, 830

**Patient-controlled analgesia;** morphine sulfate; and intrathecal vs. PCA alone, postoperative pain therapy, 958; Baxter Infusor, postoperative pain therapy, 342

**Patients**

- inpatients; amphotericin B, DUE criteria, 809; antidiotoxin monoclonal antibodies, DUE criteria, 257; DUE criteria, therapy, extrapyramidal side effects, 553; omeprazole, DUE criteria, 177; zidovudine, DUE criteria, 63
- outpatients; aminophylline, theophylline, DUE criteria, 1033; DUE criteria, therapy, extrapyramidal side effects, 553; omeprazole, DUE criteria, 177; sumatriptan, DUE criteria, 972; zidovudine, DUE criteria, 63

**Pediatrics**

- amphotericin B; candidiasis therapy, burns, infant, 883
- analgesics and antipyretics; fever therapy, review, 1005
- antibodies; monoclonal antiendotoxin, DUE criteria, 257
- antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553
- antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553
- benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553
- ceftriaxone; i.m., concentrated, pharmacokinetics, toxicity, 961
- didanosine; DUE criteria, 885
- diphtheria and tetanus toxoids and pertussis vaccines; marketing, FDA approvals, 290
- ethosuximide and phenobarbital; clearance, peritoneal dialysis, 1030
- fluconazole; candidiasis therapy, lack, burns, infant, 883
- Haemophilus b* oligosaccharide conjugate vaccines; equivalency, immunogenicity, 332
- Haemophilus b* polysaccharide conjugate vaccines; equivalency, immunogenicity, 332
- neonates; beractant, DUE criteria, 357; ciprofloxacin blood levels, maternal administration, 352; Exosurf Neonatal, DUE criteria, 355; pulmonary surfactant, adult respiratory distress syndrome therapy, 880
- pain; therapy, protocols, infants and neonates, 391
- parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553
- phenobarbital and ethosuximide; clearance, peritoneal dialysis, 1030
- phenobarbital and ethosuximide; clearance, peritoneal dialysis, 1030
- zidovudine, DUE criteria, 63

**Pfizer Pharmaceuticals;** azithromycin; marketing delay, 218

**Pharmacokinetics**

- acetaminophen; fever therapy, pediatrics, review, 1005
- aldesleukin, 669
- anti-infective agents; absorption, intraperitoneal, CAPD, 246
- aspirin; fever therapy, pediatrics, review, 1005
- azithromycin, 98, 137
- cefpodoxime proxetil, 99
- cefoxitin, 295
- ceftriaxone; i.m., concentrated, pediatrics, 961
- clarithromycin, 98, 137
- didanosine, 4
- diphtheria and tetanus toxoids and pertussis vaccines; pediatrics, 290
- doxazosin mesylate; review, 415
- felodipine, 9
- fentanyl; transdermal patches, pain therapy, 22
- finasteride, 825
- flumazenil, 287
- foscarnet sodium, 4
- ibuprofen; fever therapy, pediatrics, review, 1005
- idarubicin, 152
- $\gamma$ -interferon; review, 834
- interferon gamma-1b; review, 834
- lomefloxacin hydrochloride, 458; review, 753
- mesalamine, 514
- metoclopramide hydrochloride; peritoneal dialysis, 174
- nabumetone, 381
- olsalazine sodium, 514
- ondansetron hydrochloride; therapy, cisplatin toxicities, 1026
- oxaprozin, 591

pamidronate disodium, 220

pravastatin sodium, 99; hypercholesterolemia therapy, review, 677

quinapril hydrochloride, 220

serotonin reuptake inhibitors; depression, therapy, review, 930

sertraline hydrochloride, 381

simvastatin, 290

sumatriptan succinate; migraine therapy, review, 919

temafloxacin hydrochloride, 381; review, 753

ticlopidine hydrochloride, 99; review, 603

verapamil hydrochloride; equivalency, intact capsules vs. sprinkled on food, 539

**Pharmacy, institutional, hospital**

- quality assurance; programs, adenosine, DUE criteria, 727; programs, aminophylline, theophylline, DUE criteria, 1033; programs, amphotericin B, DUE criteria, 809; programs, antiendotoxin monoclonal antibodies, DUE criteria, 257; programs, beractant, DUE criteria, 357; programs, didanosine, DUE criteria, 885; programs, DUE criteria, therapy, extrapyramidal side effects, 553; programs, Exosurf Neonatal, DUE criteria, 355; programs, omeprazole, DUE criteria, 177; programs, skeletal muscle relaxants, DUE criteria, 435; programs, sumatriptan DUE criteria, 972; programs, zidovudine, DUE criteria, 63

**Phenobarbital;** and ethosuximide; clearance, peritoneal dialysis, 1030

**Phenylpropanolamine hydrochloride;** toxicity; hypertension, lack, 168

**Phenytoin;** eclampsia; and preeclampsia therapy, 236

**Pipercuronium bromide;** use; evaluation, criteria, 435

**Placental transfer;** scopolamine; transdermal patches, hyperemesis gravidarum therapy, 830

**Plants;** herbs; cognition disorders therapy, FDA approvals, 467

**Platelet aggregation inhibitors**

- hydroxyfibrinogenemia; therapy, 968
- ticlopidine hydrochloride; cerebrovascular disorders therapy, review, 603

**Pneumonia;** 566C80; *P. carinii*, treatment IND, FDA approvals, 99

**Poisoning;** dapsone; therapy, 800

**Polyethylene glycol;** combination, electrolytes; gastric lavage, diabetes mellitus, protocols, 751

**Pravastatin sodium**

- hypercholesterolemia; therapy, review, 677
- marketing; FDA approvals, 99

**Preeclampsia;** therapy, 236

**Pregnancy**

- angiotensin-converting enzyme inhibitors; risks, labeling, warnings, 467
- methotrexate; ectopic, therapy, 529
- scopolamine; hyperemesis gravidarum therapy, transdermal patches, 830

**Prilocaine;** combination, lidocaine; anesthesia, pain, s.c. injection sites, 347

**Product withdrawal**

- azithromycin; Pfizer, marketing delay, 218
- temafloxacin hydrochloride; toxicity, FDA regulations, 747
- triazolam; United Kingdom, 9

**Prolactin inhibitors**

- amantadine; hyperprolactinemia therapy, psychotropic toxicity, 851
- bromocriptine; hyperprolactinemia therapy, psychotropic toxicity, 851

**Propranolol;** gastrointestinal hemorrhage; prophylaxis, cirrhosis, esophageal varices, 337

**Prostatic hypertrophy;** finasteride; therapy, FDA approvals, 825

**Prothrombin time**

- tetracycline hydrochloride; interactions, warfarin, potentiation, 806
- warfarin sodium; interactions, tetracycline, potentiation, 806

**Protocols**

- adenosine; DUE criteria, 727
- alcohols, cetyl, combination, colfosceril palmitate, tylospalp; DUE criteria, 355

American Society of Hospital Pharmacists; antimicrobial prophylaxis, surgery, 483; globulin immune, i.v. therapy, 117

aminophylline; DUE criteria, 1033

amphotericin B; bladder irrigation, DUE criteria, 809

antibodies; monoclonal antiendotoxin, DUE criteria, 257

antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553

antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553

benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553

beractant; DUE criteria, 357

didanosine; DUE criteria, 885

electrolytes, combination, polyethylene glycol; gastric lavage, diabetes mellitus, 751

566C80; *P. carinii* pneumonia, treatment IND, FDA approvals, 99

omeprazole; ulcers, peptic esophagitis, therapy, DUE criteria, 177

pain; therapy, 309, 391

parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553

skeletal muscle relaxants; DUE criteria, 435

sumatriptan; DUE criteria, 972

taxol; treatment IND, FDA approvals, 912

theophylline; DUE criteria, 1033

zidovudine; DUE criteria, 63

**Puritus;** ursodiol; therapy, biliary cirrhosis, 672

**Psychotherapeutic agents**

- toxicity; extrapyramidal side effects, therapy, DUE criteria, 555
- toxicity; hyperprolactinemia, therapy, 851

**Pulmonary surfactants**

- alcohols, cetyl, combination, colfosceril palmitate, tylospalp; adult respiratory distress syndrome therapy, neonate, 880; DUE criteria, 355
- beractant; DUE criteria, 357

**Purchasing;** zalcitabine; quality problems, AIDS buyers groups, 385

**R**

**Quality assurance;** hospital pharmacy; programs, adenosine, DUE criteria, 727; programs, aminophylline, theophylline, DUE criteria, 1033; programs, amphotericin B, DUE criteria, 809; programs, antiendotoxin monoclonal antibodies, DUE criteria, 257; programs, beractant, DUE criteria, 357; programs, didanosine, DUE criteria, 885; programs, DUE criteria, therapy, extrapyramidal side effects, 553; programs, Exosurf Neonatal, DUE criteria, 355; programs, omeprazole, DUE criteria, 177; programs, skeletal muscle relaxants, DUE criteria, 435; programs, sumatriptan DUE criteria, 972; programs, zidovudine, DUE criteria, 63

**Quinapril hydrochloride;** marketing; FDA approvals, 220

**Quinolones**

- ciprofloxacin hydrochloride; blood and milk levels, 352
- lomefloxacin hydrochloride; FDA approvals, 458; pharmacology, review, 753
- temafloxacin hydrochloride; FDA approvals, 381; pharmacology, review, 753; product withdrawal, toxicity, FDA regulations, 747

**Rabies;** immunization; vaccines, human rabies immune globulin, 37

**Rabies immune globulin;** immunization, 37

**Rabies vaccines;** human diploid cell; immunization, 37

**Rational therapy;** antiarrhythmic agents, 714

**Regulations**

- Food and Drug Administration; astemizole, terfenadine, warning labels, cardiovascular toxicity, 825; cognition activator marketing, 467; zalcitabine, quality problems, premarketing access, 385
- labeling; ACE inhibitors, warnings, risks, pregnancy, 467
- new-drug applications; approvals, changes, FDA processing, 574
- temafloxacin hydrochloride; product withdrawal, FDA, 747

**Respiratory distress syndrome**

- alcohols, cetyl, combination, colfosceril palmitate, tylospalp; adult, therapy, neonate, 880; therapy, DUE criteria, 355
- beractant; therapy, DUE criteria, 357

**Respiratory smooth-muscle relaxants**

- aminophylline; availability, enteral administration, 428; DUE criteria, 1033
- theophylline; DUE criteria, 1033

**Respiratory tract infections**

- azithromycin; therapy, FDA approvals, 98; therapy, marketing delay, Pfizer, 218
- clarithromycin; therapy, FDA approvals, 98

**Reye's syndrome;** aspirin; toxicity, fever therapy, pediatrics, 1005

**Roentgenographic agents;** ionic; epidural, toxicity, inadvertent intrathecal injection, 105

**S**

**Sales;** triazolam; product withdrawal, United Kingdom, 9

**Saline, see Sodium chloride**

**Scopolamine;** hyperemesis gravidarum; transdermal patches, 830

**Seizures;** cefazolin sodium; toxicity, intraventricular injections, 104

**Self-study Materials;** *Concepts in Oncology Therapeutics, A Self-Instructional Course*, 568

**Sepsis;** antibodies; antienterotoxin monoclonal, therapy, 223; antienterotoxin monoclonal, therapy, criteria, 255; antienterotoxin monoclonal, therapy, DUE criteria, 257

**Serotonin agonists**

sumatriptan; DUE criteria, 972

sumatriptan succinate; migraine therapy, review, 919

**Sertraline hydrochloride**

depression; therapy, review, 930

marketing; FDA approvals, 381

**Shock;** antibodies; septic, antienterotoxin monoclonal, therapy, 223

**Simvastatin;** marketing; FDA approvals, 290

**Skeletal muscle relaxants**

atracurium besylate; DUE criteria, 435

doxacurium chloride; DUE criteria, 435

metocurine iodide; DUE criteria, 435

midazolam hydrochloride; muscle spasticity therapy, morphine toxicity, 57

pancuronium bromide; DUE criteria, 435

pipercuronium bromide; DUE criteria, 435

tubocurarine chloride; DUE criteria, 435

vecuronium bromide; DUE criteria, 435

**Skin diseases**

aztreonam; therapy, FDA approvals, 98

clarithromycin; FDA approvals, 98

**Sodium chloride;** comparison, heparin; i.v. lock flushing, 797

**Sucralfate**

interference; occult blood tests, Gastrocult vs. Hemoccult, 625

toxicity; aluminum overload, deferoxamine therapy, CAPD, 636

**Sumatriptan;** use; evaluation, criteria, 972

**Sumatriptan succinate;** migraine; therapy, review, 919

**Surgey**

anesthetics; abdominal, toxicity, nausea and vomiting, 965

anti-infective agents; prophylaxis, ASHP protocols, 483

dental; hemorrhage prophylaxis, anticoagulant toxicity, 857

protocols; pain therapy, 309, 391

**Sustained-action medications**

calcium antagonists; therapy, improved patient compliance, 549

verapamil hydrochloride; intact capsules vs. sprinkled on food, pharmacokinetics, 539

**Sympatholytic agents**

β blockers; hyperfibrinogenemia therapy, 968

nadolol; gastrointestinal hemorrhage, prophylaxis, cirrhosis, esophageal varices, 337

propranolol; gastrointestinal hemorrhage, prophylaxis, cirrhosis, esophageal varices, 337

**Sympathomimetic agents**

β agonists; aerosols, dosage schedules, asthma therapy, 877; asthma therapy, controversies, 13

phenylpropanolamine hydrochloride; toxicity, hypertension, lack, 168

**T**

**Tachycardia;** adenosine; paroxysmal supraventricular, therapy, DUE criteria, 727

**Taxol;** ovarian neoplasms; treatment IND, FDA approvals, 912

**Tenafloxacin hydrochloride**

marketing; FDA approvals, 381

pharmacology; review, 753

product withdrawal; toxicity, FDA regulations, 747

**Teratogenicity**

angiotensin-converting enzyme inhibitors; pregnancy, labeling, warnings, 467

scopolamine; placental transfer, hyperemesis gravidarum transdermal therapy, 830

**Terfenadine;** toxicity; cardiovascular, labeling, warnings, 825

**Tests, laboratory**

cholesterol; and HDL monitoring, coronary disease

378

occult blood; Gastrocult vs. Hemoccult, interference, sucralose, 625

**Tetracycline hydrochloride;** interactions; warfarin, potentiation, prothrombin time, 806

**Tetracyclines;** tetracycline hydrochloride; interactions, warfarin, potentiation, prothrombin time, 806

**Theophylline**

blood levels; aminophylline availability, enteral administration, 428

use; evaluation, criteria, 1033

**Therapy Consultation,** 672, 751, 830, 917

Diabetes control during bowel cleansing with PEG-electrolyte solution, 751

Erythromycin, motilin, and gastroparesis, 917

Transdermal scopolamine for hyperemesis gravidarum, 830

Use of ursodiol in a patient with biliary cirrhosis, 672

**Thrombocytopenia;** heparin; toxicity, i.v. lock flushing, 797

**Thromboembolism;** heparin; toxicity, i.v. lock flushing, 797

**Ticlopidine hydrochloride**

cerebrovascular disorders; therapy, review, 603

marketing; FDA approvals, 99

**Topical preparations**

fentanyl; transdermal patches, pain therapy, 22

lidocaine, combination, prilocaine; creams, anesthesia, pain, s.c. injection sites, 347

**Toxicity**

acetaminophen; fever therapy, pediatrics, review, 1005

adenosine; DUE criteria, 727

β agonists; regular vs. as-needed, asthma, 877

alcohols, cetyl, combination, colfosceril palmitate, tyloxaol; DUE criteria, 355

aldesleukin, 669

aminophylline; DUE criteria, 1033

amphotericin B; DUE criteria, 809

anesthetics; nausea and vomiting, abdominal surgery, 965

angiotensin-converting enzyme inhibitors; pregnancy, labeling, warnings, 467

antiarrhythmic agents, 714; interactions, implanted cardiac devices, 48

antibodies; monoclonal antienterotoxin, DUE criteria, 257

anticoagulants; hemorrhage, dental surgery, 857

antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553

anti-infective agents; postantibiotic effect, factors, 865

anti-inflammatory agents; nonsteroidal, ulcers, therapy, review, 690

antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553

aspirin; Reye's syndrome, fever therapy, pediatrics, 1005

astemizole; cardiovascular, labeling, warnings, 825

azithromycin; side effects, 98, 137; side effects, marketing delay, Pfizer, 218

benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553; overdose, flumazenil therapy, 287

beractant; DUE criteria, 357

β blockers; side effects, gastrointestinal hemorrhage prophylaxis, 337

calcium antagonists; side effects, 549

cefazolin sodium; seizures, intraventricular injections, 104

cefpodoxime proxetil, 999

cefprozil, 295

ceftriaxone; side effects, lack, i.m., concentrated, pediatrics, 961

cisplatin; ondansetron therapy, pharmacokinetics, 1026

clarithromycin; side effects, 98, 137

dapsone; hemolytic anemia, methemoglobinemia, therapy, 800

didanosine, 4; DUE criteria, 885

digoxin; nonsteroidal, toxicity, 450

drugs; endocrine disorders, HIV infections, therapy, 705; measuring cups, spoons, droppers, dosing problems, 220

felodipine, 9

fentanyl; transdermal, side effects, 22

finasteride, 825

flumazenil, 287

foscarnet sodium, 4

ganciclovir; liver, cytomegalic inclusion disease therapy, AIDS, 432

globulin immune; reconstitution, dextrose vs. water for injection, lack, 628; side effects, concentrated injections, 1022

**Haemophilus b oligosaccharide conjugate vaccines;** side effects, pediatrics, 332

**Haemophilus b polysaccharide conjugate vaccines;** side effects, pediatrics, 332

heparin; flushes, thrombocytopenia, thromboembolism, 797

ibuprofen; fever therapy, pediatrics, review, 1005

idarubicin; side effects, 152

injections; pain, lidocaine-prilocaine topical anesthesia, 347

γ-interferon; side effects, review, 834

interferon gamma-1b; side effects, review, 834

lomefloxacin hydrochloride; side effects, 458, 753

mesalamine; side effects, 514

methotrexate; side effects, ectopic pregnancy therapy, 529

morphine sulfate; Baxter Infusor, PCA, postoperative pain therapy, 342; muscle spasticity, midazolam therapy, 57; side effects, intrathecal and i.v. PCA vs. PCA alone, 958

nabumetone, 381

nutrition; parenteral, home therapy, 543

olsalazine sodium; side effects, 514

omeprazole; side effects, DUE criteria, 177

oxaprozin; side effects, 591

panidronate disodium, 220

parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553

phenylpropanolamine hydrochloride; hypertension, lack, 168

pravastatin sodium; side effects, 99; side effects, hypercholesterolemia therapy, review, 677

psychotherapeutic agents; extrapyramidal side effects, therapy, DUE criteria, 553; hyperprolactinemia, therapy, 851

quinapril hydrochloride, 220

roentgenographic agents; ionic, inadvertent intrathecal injection, 105

scopolamine; placental transfer, hyperemesis gravidarum transdermal therapy, 830

serotonin reuptake inhibitors; side effects, depression therapy, review, 930

sertraline hydrochloride, 381

simvastatin, 290

skeletal muscle relaxants; DUE criteria, 435

sucralfate; aluminum overload, deferoxamine therapy, CAPD, 636

**sumatriptan;** DUE criteria, 972

sumatriptan succinate; side effects, migraine therapy, review, 919

temafloxacin hydrochloride, 381; side effects, 753

terfenadine; cardiovascular, labeling, warnings, 825

theophylline; DUE criteria, 1033

ticlopidine hydrochloride; side effects, 99; side effects, review, 603

triazolam; side effects, product withdrawal, United Kingdom, 9

verapamil hydrochloride; side effects, lack, intact capsules vs. sprinkled on food, 539

warfarin sodium; interactions, tetracycline, potentiation, prothrombin time, 806; intramural hematoma of the small intestine, 632

zalcitabine, 747

zidovudine; DUE criteria, 63

**Tranexamic acid;** hemorrhage; prophylaxis, dental surgery, anticoagulant toxicity, 857

**Transplantation;** bone marrow; adult acute leukemia, therapy, review, 767; globulin immune, concentrated injections, toxicity, 1022

**Triazolam**

labeling; changes, FDA approvals, 467

product withdrawal; United Kingdom, 9

**Tubocurarine chloride;** use; evaluation, criteria, 435

**Tyloxaol;** combination, alcohols, cetyl, colfosceril palmitate; adult respiratory distress syndrome therapy, neonate, 880; use evaluation criteria, 355

**U**

**Ulcers**

anti-inflammatory agents; nonsteroidal, toxicity, review, 690

omeprazole; duodenal, gastric, therapy, DUE criteria, 177

**United Kingdom;** triazolam; product withdrawal, 9

**Urinary tract infections;** amphotericin B; therapy, DUE criteria, 809

**Ursodiol;** pruritus; therapy, biliary cirrhosis, 672

## Annual Index

### V

#### Vaccines

diphtheria and tetanus toxoids and pertussis; marketing, FDA approvals, 290  
*Haemophilus b* oligosaccharide conjugate; equivalency, immunogenicity, pediatrics, 332  
*Haemophilus b* polysaccharide conjugate; equivalency, immunogenicity, pediatrics, 332  
rabies; human diploid cell, immunization, 37  
*Varicella-zoster*; intraperitoneal; absorption, CAPD, 246  
**Vasodilating agents**; hyperfibrinogenemia; therapy, 968  
**Vecuronium bromide**; use; evaluation, criteria, 435  
**Vehicles**  
dextrose, comparison, water for injection; globulin immune reconstitution, toxicity, 628  
water for injection, comparison, dextrose; globulin immune reconstitution, toxicity, 628  
**Verapamil hydrochloride**; pharmacokinetics; equivalency, intact capsules vs. sprinkled on food, 539

**Vitamins**; marketing; cognition disorders therapy, FDA disapprovals, 467  
**Volume of distribution**, see **Drugs, body distribution**

#### Vomiting

anesthetics; and nausea, toxicity, surgery, 965  
ondansetron hydrochloride; and nausea, therapy, cisplatin toxicity, 1026

### W

#### Warfarin sodium

interactions; tetracycline, potentiation, prothrombin time, 806  
toxicity; intramural hematoma of the small intestine, 632  
**Water for injection**; comparison, dextrose; globulin immune reconstitution, toxicity, 628  
**Weight**; patients; nausea and vomiting, anesthetics toxicity, surgery, 965  
**Wounds and injuries**; protocols; pain therapy, 309, 391

### X

#### Xomen-E5

sepsis; antiendotoxin monoclonal antibodies, therapy, 223; antiendotoxin monoclonal antibodies, therapy, criteria, 255  
use; evaluation, criteria, 257

### Z

#### Zalcitabine

marketing; FDA approvals, accelerated drug review policy, 747  
purchasing; AIDS buyers groups, quality problems, 385

#### Zidovudine

and zalcitabine; HIV infections, combined therapy, 747  
use; evaluation, criteria, 63

## Author Index

### A

**Acosta, Mark A.** see Bradley, John S., 961  
**Adams, Margaret A.** see Kozloski, Gary D., 539  
**Agency for Health Care Policy and Research** Acute pain management: operative or medical procedures and trauma, part 1, 309; part 2, 391  
**Anderson, Douglas C. Jr.** see Sagraves, Rosalie, 830  
**ASHP Commission on Therapeutics** ASHP therapeutic guidelines for intravenous immune globulin, 117  
**ASHP Commission on Therapeutics** ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery, 483  
**Avent, Minyon L.** Warfarin-induced intramural hematoma of the small intestine, 632

### B

**Babamoto, Kenneth S.** Doxazosin: a new  $\alpha_1$ -adrenergic antagonist, 415  
**Bagwell, J. Todd** see Martin, Emory S. III, 104  
**Baile, George R.** see Figge, Helen L., 432  
**Banner, William Jr.** Use of succimer (letter), 388  
**Barone, Joseph A.** see Frenta, Maureen L., 37  
**Barriere, Steven L.** Gram-negative sepsis, the sepsis syndrome, and the role of antifendotoxin monoclonal antibodies, 223  
**Barton, Terri L.** see Chan, C. Y. Jennifer, 880  
**Batra, Kumar K.** see Marquardt, Eric D., 1030  
**Bauman, Jerry L.** see Tworek, Deborah A., 48  
**Bay, William** see Gora, Mary Lea, 174  
**Benson, John M.** Nausea and vomiting after abdominal surgery, 965  
**Bernstein, Linda R.** see Herfindal, Eric T., 543  
**Bezaro, Edward R.** see Wermeling, Daniel P., 342  
**Bhatt-Mehta, Varsha** Criteria for use of colfosciril (Exosurf Neonatal) in neonates, 355  
**Birmingham, William E.** see Littrell, Robert A., 57  
**Bjornson, Darrel C.** see Cortese, Linda M., 675, 885  
**Blake, Kathryn V.** see Hill, Malcolm R., 877  
**Bolinger, Ann M.** Recombinant interferon gamma for treatment of chronic granulomatous disease and other disorders, 834  
**Boucher, Bradley A.** see Wermeling, Daniel P., 342  
**Bowden, Talmadge A. Jr.** see Benson, John M., 965  
**Bradley, John S.** Pharmacokinetics and safety of intramuscular injection of concentrated ceftazidime in children, 961  
**Briceland, Laurie L.** see Figge, Helen L., 432  
**Briggs, Gerald G.** see Wermeling, Daniel P., 342  
**Brocavich, Joseph M.** see Etzel, Joseph V., 705  
**Bush-Veith, Stacie** see Martin, Emory S. III, 104

### C

**Calis, Karim Anton** Transdermally administered fentanyl for pain management, 22  
**Calis, Karim A.** see also Kohler, David R., 584  
**Calis, Karim Anton** see also Yurkowski, Peter J., 917  
**Canaday, Bruce R.** see Avent, Minyon L., 632

**Cantral, Kimberly A.** see Jungnickel, Paul W., 677  
**Capparelli, Edmund V.** New calcium-channel blockers: improved therapy? 549  
**Cersosimo, Robert J.** Idoxuridine: an anthracycline antineoplastic agent, 152  
**Chan, C. Y. Jennifer** Colfosciril in an infant with adult respiratory distress syndrome, 880  
**Chandler, Mary H. H.** see Parr, Michael D., 1026  
**Chin, Barbara** see Marquardt, Eric D., 1030  
**Coleman, Cathy L.** see Benson, John M., 965  
**Compogniannis, Lisa S.** see Bradley, John S., 961  
**Coonce, Shannon L.** Beta-adrenergic agonists in asthma (letter), 14  
**Coonce, Shannon L.** see also Simon, Pamela A., 387  
**Corso, Diane M.** see Calis, Karim Anton, 22  
**Corso, Diane M.** see also Kohler, David R., 584  
**Cortese, Linda M.** Criteria for use of didanosine in adult and pediatric patients, 885  
**Cortese, Linda M.** Potential interaction between terfenadine and macrolide antibiotics (letter), 675

### D

**Danos, Erica A.** Apparent potentiation of warfarin activity by tetracycline, 806  
**Danziger, Larry H.** see Piscitelli, Stephen C., 137  
**Darbinian, Jeanne A.** see Herfindal, Eric T., 543  
**D'Elia, John A.** see Min, David I., 636  
**De Vito, Joseph M.** see Kozloski, Gary D., 539  
**Devane, C. Lindsay** Book review, 277  
**DiPiro, Joseph T.** see Benson, John M., 965  
**DiPiro, Joseph T.** see also Hardin, Thomas C., 255  
**Donnelly, Andrew J.** Criteria for use of pancuronium bromide, vecuronium bromide, atracurium besylate, tubocurarine chloride, metocurine iodide, pipecuronium bromide, and doxacurium chloride in adults, 435  
**Donnigan, L. Deanne** see Benson, John M., 965  
**Drwal-Klein, Laureen A.** Antipyretic therapy in the febrile child, 1005

### E

**Ebert, Steven C.** Characterization of the postantibiotic effect, 876  
**Elder, Cheryl A.**  $\beta$ -Adrenergic antagonists for primary prevention of gastrointestinal hemorrhage in patients with cirrhosis and esophageal varices, 337  
**Ernst, Edzard** Lowering the plasma fibrinogen concentration with drugs, 968  
**Ernst, Edzard** Treating ischemic stroke: is nimodipine the answer? 350  
**Erstad, Brian L.** Dapsone-induced methemoglobinemia and hemolytic anemia, 800  
**Etzel, Joseph V.** Endocrine complications associated with human immunodeficiency virus infection, 705  
**Ezell, Jeanne R.** see Marken, Patricia A., 553  
**Erzi, Marilyn** see Tworek, Deborah A., 48

### F

#### Fankhauser, Martha P.

Book review, 655  
**Figge, Helen L.** Possible ganciclovir-induced hepatotoxicity in patients with AIDS, 432  
**Fisher, Joseph N.** see Marken, Patricia A., 851  
**Flynn, Patrice L.** Topical capsaicin for osteoarthritis (letter), 308  
**Foster, Thomas S.** see Wermeling, Daniel P., 342  
**Frenia, Maureen L.** Features and treatment of rabies, 37

### G

**Gabbe, Steven G.** see Gardner, Debra K., 352  
**Gales, Barry J.** see Segars, Larry W., 514  
**Gardner, Debra K.** Simultaneous concentrations of ciprofloxacin in breast milk and in serum in mother and breast-fed infant, 352  
**Garrett, James C.** White clot syndrome and thrombocytopenia: reasons to abandon heparin i.v. lock flush solution, 797  
**Golembiewski, Julie A.** see Donnelly, Andrew J., 435  
**Goodwin, S. Diane** Criteria for use of zidovudine in adult and pediatric inpatients and outpatients, 63  
**Gora, Mary Lea** Pharmacokinetics of intraperitoneal metoclopramide in a patient with renal failure, 174  
**Greene, Stan A.** see Wermeling, Daniel P., 342  
**Grimsley, Sara R.** Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors, 930  
**Guglielmo, B. Joseph** see Barriere, Steven L., 223

### H

**Haas, Curtis E.** Book review, 565  
**Hardin, Thomas C.** Who should receive antiendotoxin monoclonal antibody therapy? (editorial), 255  
**Harter, Chris** see Gardner, Debra K., 352  
**Haykal, Radwan F.** see Marken, Patricia A., 851  
**Healy, Daniel P.** Book review, 900  
**Hecker, Earl T.** see Wetmore, Robert W., 958  
**Henderson, Lisa M.** see Parr, Michael D., 1026  
**Herfindal, Eric T.** Complications of home parenteral nutrition, 543  
**Herzfeld, Jeff** see Nee, Chris, 13  
**Hill, Malcolm R.** Regularly scheduled versus as-needed use of inhaled  $\beta$  agonists in the treatment of asthma, 877  
**Hirokawa, William T.** see Babamoto, Kenneth S., 415  
**Hirsch, Jan D.** see Benson, John M., 965  
**Hogue, Valerie W.** see Herfindal, Eric T., 543  
**Holman, Jonathan S.** Influence of sucralase on the detection of occult blood in simulated gastric fluid by two screening tests, 625  
**Holmes, Gregory B.** see Kozloski, Gary D., 539  
**Hsu, Van Doren** Criteria for use of sumatriptan in adult inpatients and outpatients, 972  
**Hsu, Van Doren** Sumatriptan: a new drug for vascular headache, 919  
**Huber, Steven** see Ippoliti, Cindy, 1022  
**Hunt, Thomas L.** see Kozloski, Gary D., 539

**I**

Ignoffo, Robert J. Self-study materials review, 568  
 Ippoliti, Cindy Toxicity of rapidly infused concentrated intravenous immune globulin, 1022  
 Ishisaka, Denis Y. see Marquardt, Eric D., 1030  
 Ito, Matthew K. Ticlopidine: a new platelet aggregation inhibitor, 603

**J**

Jacobson, Pamela A. see Montgomery, Patricia A., 809  
 Jann, Michael W. see Grimsley, Sara R., 930  
 Johnson, Jerry B. see Kozloski, Gary D., 539  
 Jones, Daniel W. see Sands, Charles D., 168  
 Joubert, Dennis W. Value of transdermal fentanyl (letter), 584  
 Jung, Kyung M. see Sands, Charles D., 168  
 Jungnickel, Paul W. Pravastatin: a new drug for the treatment of hypercholesterolemia, 677

**K**

Kalt, Mark A. see Wetmore, Robert W., 958  
 Kane, Bud J. Book review, 901  
 Kennedy, L. Douglas see Littrell, Robert A., 57  
 Kim, Hyun Jong see Sands, Charles D., 168  
 Kohler, David R. Value of transdermal fentanyl (letter), 584  
 Kohler, David R. see also Calis, Karim Anton, 22  
 Koren, Gideon see Taddio, Anna, 347  
 Korones, Sheldon B. see Prevost, Rebecca Rogers, 357  
 Kowalsky, Steven F. see Figge, Helen L., 432  
 Kozloski, Gary D. Bioequivalence of verapamil hydrochloride extended-release pellet-filled capsules when opened and sprinkled on food and when swallowed intact, 539  
 Kuhn, John G. see Kane, Bud J., 901

**L**

Lafin, Suzanne M. see Frenia, Maureen L., 37  
 Lajoie, Caroline Criteria for use of omeprazole in adult patients and outpatients, 177  
 Leah, W. David see Littrell, Robert A., 57  
 Lee, Marisa L. see Ito, Matthew K., 603  
 Lehman, Mark E. see Wermeling, Daniel P., 342  
 Lindley, Celeste Book review, 92  
 Ling, Frank W. see Prevost, Rebecca Rogers, 529  
 Littrell, Robert A. Muscle spasms associated with intrathecal morphine therapy: Treatment with midazolam, 57

**M**

MacDonald, John S. see Parr, Michael D., 1026  
 Maloley, Pierre A. see Jungnickel, Paul W., 677  
 Mann, Katherine V. Use of succimer (letter), 388  
 Marcus, Steven M. Use of succimer (letter), 387  
 Marken, Patricia A. Criteria for use of agents for extrapyramidal adverse effects in adult, adolescent, and child inpatients and outpatients, 553  
 Marken, Patricia A. Management of psychotropic-induced hyperprolactinemia, 851  
 Marquardt, Eric D. Removal of ethosuximide and phenobarbital by peritoneal dialysis in a child, 1030  
 Martin, Emory S. III Danger of epirdural use of ionic contrast media (letter), 105  
 Martin, Emory S. III Seizures after intraventricular ceftazolin administration (letter), 104  
 Mason, Nancy A. see O'Brien, Maureen A., 246  
 Mauro, Laurie S. see Mauro, Vincent F., 897  
 Mauro, Vincent F. Book review, 897  
 McCauley, Dayna L. Treatment of adult acute leukemia, 767  
 McCollum, Patrick L. see Morales, Enid, 727  
 McCombs, Janet Treatment of preeclampsia and eclampsia, 236  
 McIntrye, William J. see Parr, Michael D., 1026  
 McMahon, Teresa Diabetes control during bowel cleansing with PEG-electrolyte solution (Therapy Consultation), 751  
 Miller, Donald R. Treatment of nonsteroidal anti-inflammatory drug-induced gastropathy, 690  
 Miller, Kenneth B. Safety and tolerability of an intravenous immune globulin at various concentrations in

5% dextrose injection or sterile water for injection, 628  
 Miller, Lucinda G. Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug, 591  
 Min, David I. Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine, 636  
 Mirro, Robert see Prevost, Rebecca Rogers, 357  
 Montgomery, Patricia A. Criteria for use of amphotericin B bladder irrigation in adult inpatients, 809  
 Morales, Enid Criteria for use of adenosine in adults with paroxysmal supraventricular tachycardia, 727  
 Mowatt-Larsen, Christine A. Working group issues report on aluminum contamination of parenteral nutrient solutions (News), 6  
 Murphy, Christine M. see Coonce, Shannon L., 14  
 Murphy, Christine M. see also Simon, Pamela A., 387  
 Murray, William E. see Bradley, John S., 961

**N**

Nazari, José see Tworek, Deborah A., 48  
 Nee, Chris Beta-adrenergic agonists in asthma (letter), 13  
 Nix, David E. see Symonds, William T., 753

**O**

O'Brien, Maureen A. Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis, 246

**P**

Parr, Michael D. Pharmacokinetics of ondansetron in patients receiving cisplatin therapy, 1026  
 Patterson, Larry E. Book review, 901  
 Phelps, Stephanie J. see Drwal-Klein, Laureen A., 1005  
 Phillips, Marjorie Shaw Criteria for use of theophylline (aminophylline) in inpatients and outpatients with pulmonary disease, 1033  
 Pickworth, Kerry L. Long-term dobutamine therapy for refractory congestive heart failure, 618  
 Pinson, Julianne B. New considerations for *Haemophilus influenzae* type b vaccination, 332  
 Piscitelli, Stephen C. Clarithromycin and azithromycin: new macrolide antibiotics, 137  
 Prevost, Rebecca Rogers Criteria for use of beractant (Survanta) in neonates, 357  
 Prevost, Rebecca Rogers Methotrexate for treatment of unruptured ectopic pregnancy, 529

**R**

Rasch, Deborah K. see Chan, C. Y. Jennifer, 880  
 Reitberg, Donald P. see Sanders, Steven W., 533  
 Renger, Harvey Jr. see Martin, Emory S. III, 104  
 Restino, Maryann S. Reynolds see Elder, Cheryl A., 337  
 Robieux, Isabelle see Taddio, Anna, 347  
 Rodvold, Keith A. see Piscitelli, Stephen C., 137  
 Ruck, Bruce see Marcus, Steven M., 387

**S**

Sagraves, Rosalie Transdermal scopolamine for hyponemesis gravidarum (Therapy Consultation), 830  
 Sahn, Steven A. see Shalansky, Karen F., 428  
 Sanders, Steven W. Effect of a single dose of lactase on symptoms and expired hydrogen after lactose challenge in lactose-intolerant subjects, 533  
 Sands, Charles D. Effect of propantheline hydrochloride on blood pressure in Korean patients with hypertension controlled by hydrochlorothiazide, 168  
 Sawyer, William T. see Avent, Minyon L., 632  
 Schenkein, David P. see Miller, Kenneth B., 628  
 Schoenbrun, Karen J. Book review, 373  
 Schumacher, Robert E. see Bhatt-Mehta, Varsha, 355  
 Segars, Larry W. Mesalamine and olsalazine: 5-amino-salicylic acid agents for the treatment of inflammatory bowel disease, 514  
 Seifert, Charles F. see Vondracek, Thomas G., 672  
 Seth, Shiv see Gora, Mary Lea, 174  
 Shalansky, Karen F. Absolute bioavailability of aminophylline liquid administered enterally in adults re-

quiring mechanical ventilation, 428  
 Shepherd, Michele F. Criteria for use of antidiotoxin monoclonal antibodies (HA-1A and E5) in adult and pediatric inpatients, 257

Shields, Brenda see Gora, Mary Lea, 174  
 Shipp, Kenneth W. see Goodwin, S. Diane, 63  
 Shwed, Jill A. see Holman, Jonathan S., 625  
 Simon, Pamela A. Asthma in children (letter), 387  
 Simon, Pamela A. see also Coonce, Shannon L., 14  
 Skupski, Richard see Donnelly, Andrew J., 435  
 Slimowitz, Richard Book review, 565  
 Smith, Alden R. see Ito, Matthew K., 603  
 Snaydon, David R. Use of cytomegalovirus immune globulin (letter), 674  
 Spivey, J. Michael The postantibiotic effect, 865  
 Stanfield, Johnny A. see Benson, John M., 965  
 Stegman, Mary see Stoukides, Cheryl A., 222  
 Stoukides, Cheryl A. Diffuse rash associated with transdermal fentanyl (letter), 222  
 Stovall, Thomas G. see Prevost, Rebecca Rogers, 529  
 Sybert, John W. see Wetmore, Robert W., 958  
 Symonds, William T. Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials, 753

**T**

Taddio, Anna Effect of lidocaine-prilocaine cream on pain from subcutaneous injection, 347  
 Taubel, Mary A. see Bolinger, Ann M., 834  
 Tisdale, James E. Are antiarrhythmic drugs obsolete? 714  
 Tisdale, James E. Book review, 277  
 Tolman, Keith G. see Sanders, Steven W., 533  
 Torre, Michael see Etzel, Joseph V., 705  
 Travers, John D. see Mann, Katherine V., 388  
 Tsu, Gloria L. see Bradley, John S., 961  
 Tweeddale, Martin G. see Shalansky, Karen F., 428  
 Tworek, Deborah A. Interference by antiarrhythmic agents with function of electrical cardiac devices, 48

**U**

Ustad, Cristina see Shalansky, Karen F., 428

**V**

Vance-Bryan, Kyle Book review, 742  
 Vaughan, Leigh M. see Shalansky, Karen F., 428  
 Visconti, James A. see Gora, Mary Lea, 174  
 Vondracek, Thomas G. Use of ursodiol in a patient with biliary cirrhosis (Therapy Consultation), 672

**W**

Wasserman, Richard L. see Miller, Kenneth B., 628  
 Weart, C. Wayne see Pinson, Julianne B., 332  
 Webb, Charles R. see Tisdale, James E., 714  
 Weiber, Robert T. Oral anticoagulant therapy in patients undergoing dental surgery, 857  
 Wermeling, Daniel P. Multicenter evaluation of a patient-controlled analgesia device for the treatment of postoperative pain, 342  
 West, Dennis see Flynn, Patrice L., 308  
 Wetmore, Robert W. Intrathecal administration of morphine followed by patient-controlled intravenous administration for postoperative analgesia, 958  
 Williams, Dennis M. Asthma in children (letter), 386  
 Williams, Loretta Ann see Ippoliti, Cindy, 1022  
 Wilson, Dean C. Fluconazole failure in a child with burns and candidemia, 883  
 Wojtynek, Jeffrey E. see Donnelly, Andrew J., 435  
 Wong, Alvin F. see Herfindal, Eric T., 543  
 Woster, Patricia S. see Montgomery, Patricia A., 809

**Y**

Yurkowski, Peter J. Erythromycin, motilin, and gastraparesis (Therapy Consultation), 917

**Z**

Zola, Elizabeth M. Use of surfactant products (letter), 583